Improvement of sexual dysfunction in patients after treatment of hepatitis C virus using directly acting antivirals.

OBJECTIVE The impact on male and female sexual dysfunction of treating hepatitis C virus (HCV) using direct-acting antiviral agents (DAAs) has not been sufficiently studied. The aim of this study was to assess the impact of HCV clearance with DAAs on sexual dysfunction (SD) in both sexes. METHODS In chronic HCV patients who were eligible for DAAs, 100 sexually active men completed the Arabic version of the international index of erectile function questionnaire (IIEF-5), and the same number of sexually active women completed Female Sexual Function Index (FSFI), before, at the end of, and three months after, treatment for HCV. RESULT The mean of the IIEF-5 scores for male patients was 16.29 ±.07 before treatment, 16.88 ± 3.63 three months after treatment (p   0.05). CONCLUSIONS Significant improvement in SD associated with HCV infection in both sexes was recorded following viral clearance using DAAs treatment.